April 22, 2002
Dana-Farber names del Campo as Vice President for Research and Technology Ventures
Anthony del Campo
Anthony A. del Campo, who has more than 20 years of biomedical research and business development experience, has been named vice president for Research and Technology Ventures at Dana-Farber Cancer Institute. Del Campo will oversee the full scope of intellectual property management, technology licensing activities and other interactions with industry, including the negotiation of industry-sponsored basic and clinical science research.
"With his wealth of biomedical business development experience in the corporate and academic settings, Tony del Campo is well-suited to help us quicken the pace of converting scientific advances made at Dana-Farber into clinical treatments for cancer patients," says Edward J. Benz, Jr. MD, president of Dana-Farber.
Del Campo comes to Dana-Farber from Genome Therapeutics Corporation in Waltham, Mass., where he was the senior director of corporate development since 1999. He was involved in various business development activities in support of the company's infectious disease and human genomics programs, including negotiating strategic partnerships and licensing agreements with pharmaceutical and biotechnology companies and academic institutions.
Prior to joining Genome Therapeutics, del Campo served as director of business development for BCM Technologies (BCMT) in Houston from 1994 to 1999. BCMT, the venture and technology transfer subsidiary of Baylor College of Medicine, is widely considered to be one of the leading academic technology transfer organizations in the country. Del Campo was responsible for the negotiation of several significant agreements with private industry. He also was instrumental in the formation of a number of start-up ventures based on technology developed at Baylor College of Medicine. From 1992 to 1994, del Campo was a licensing specialist in the Office of Technology Development at M.D. Anderson Cancer Center in Houston.
"Dana-Farber has an outstanding reputation as a center of excellence in research and clinical care," says del Campo. "I am very excited to have joined this world-class organization and to be part of the effort to ensure that the Institute's discoveries are optimally transferred to the commercial sector for further development and ultimately into the clinic setting."
Del Campo also has extensive experience in conducting biomedical research. He was a biologist at the National Cancer Institute in Bethesda, Md., 1977 to 1987, and a senior research associate for LifeCell Corporation in The Woodlands, Tex., 1987 to 1992.
Del Campo holds an MBA degree from the C.T. Bauer College of Business at University of Houston and he conducted graduate studies in cell biology at Georgetown University. He earned his undergraduate degree in biology from the University of Maryland, Baltimore County. Del Campo is a member of the Association of University Technology Managers and the Licensing Executives Society.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a National Cancer Institute-designated comprehensive cancer center.
